{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:18:26Z","timestamp":1785881906073,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jns.2024.123051","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:07:25Z","timestamp":1715940445000},"page":"123051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study"],"prefix":"10.1016","volume":"461","author":[{"given":"Noriko","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ichi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Yoritaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123051_bb0005","doi-asserted-by":"crossref","first-page":"1162016","DOI":"10.3389\/fneur.2023.1162016","article-title":"Prescribing patterns and determinants for elderly patients with Parkinson\u2019s disease in Japan: a retrospective observational study using insurance claims databases","volume":"14","author":"Seki","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.123051_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2024.123051_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14737175.2023.2176220","article-title":"Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach","volume":"23","author":"Lees","year":"2023","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jns.2024.123051_bb0020","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/ejn.14119","article-title":"L-DOPA for Parkinson's disease-a bittersweet pill","volume":"49","author":"Lane","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jns.2024.123051_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0891988720988904","article-title":"Treatment of advanced Parkinson's disease","volume":"35","author":"Gilbert","year":"2022","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.jns.2024.123051_bb0030","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","article-title":"Longitudinal analysis of impulse control disorders in Parkinson disease","volume":"91","author":"Corvol","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123051_bb0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamaneurol.2021.4736","article-title":"Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase b inhibitors compared with dopamine agonists among patients with Parkinson disease uncontrolled by levodopa therapy: the PD MED randomized clinical trial","volume":"79","author":"Gray","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123051_bb0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14740338.2022.1988926","article-title":"Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for Parkinson's disease","volume":"21","author":"Kurihara","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jns.2024.123051_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","article-title":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled, phase II\/III study","volume":"75","author":"Hattori","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2024.123051_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117012","article-title":"Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson\u2019s disease with wearing-off: results of an open-label study","volume":"416","author":"Tsuboi","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123051_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/JPD-150700","article-title":"Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson\u2019s disease fluctuating patients: post hoc analyses of studies 016 and SETTLE","volume":"6","author":"Cattaneo","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jns.2024.123051_bb0060","author":"Pharmaceuticals and Medical Devices Agency"},{"key":"10.1016\/j.jns.2024.123051_bb0065","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the motor examination part of MDS-UPDRS","volume":"21","author":"Horv\u00e1th","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2024.123051_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120083","article-title":"Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson\u2019s disease: a post hoc analysis of a Japanese phase 2\/3 study","volume":"434","author":"Nomoto","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123051_bb0075","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Schapira","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123051_bb0080","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","article-title":"The XINDI study: a randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson\u2019s disease with motor fluctuations","volume":"36","author":"Wei","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2024.123051_bb0085","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00702-022-02532-2","article-title":"Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson\u2019s disease: post-hoc analysis of a Japanese phase III study","volume":"129","author":"Hattori","year":"2022","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.jns.2024.123051_bb0090","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1080\/09638288.2022.2074152","article-title":"Minimal clinically important difference of the King\u2019s Parkinson\u2019s disease pain scale","volume":"45","author":"Taghizadeh","year":"2023","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.jns.2024.123051_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.106012","article-title":"Validation study of the Japanese version of the King\u2019s Parkinson\u2019s disease pain scale and the King\u2019s Parkinson\u2019s disease pain questionnaire","volume":"120","author":"Kurihara","year":"2024","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2024.123051_bb0100","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/jpm11080798","article-title":"Pain improvement in Parkinson\u2019s disease patients treated with safinamide: results from the SAFINONMOTOR study","volume":"11","author":"Santos Garc\u00eda","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.jns.2024.123051_bb0105","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00702-020-02218-7","article-title":"Effects of safinamide on pain in Parkinson\u2019s disease with motor fluctuations: an exploratory study","volume":"127","author":"Geroin","year":"2020","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.jns.2024.123051_bb0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/30.4.299","article-title":"Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire","volume":"30","author":"Peto","year":"2001","journal-title":"Age Ageing"},{"key":"10.1016\/j.jns.2024.123051_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118070","article-title":"Effects of safinamide adjunct therapy on pain in patients with Parkinson\u2019s disease: post hoc analysis of a Japanese phase 2\/3 study","volume":"429","author":"Tsuboi","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123051_bb0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JPD-160911","article-title":"Effects of safinamide on pain in fluctuating Parkinson\u2019s disease patients: a post-hoc analysis","volume":"7","author":"Cattaneo","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jns.2024.123051_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2017.12.031","article-title":"Pain sensitivity in Parkinson\u2019s disease: systematic review and meta-analysis","volume":"48","author":"Sung","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2024.123051_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114555","article-title":"Analgesic effect of safinamide mesylate in a rat model of neuropathic pain","volume":"452","author":"Kogo","year":"2023","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jns.2024.123051_bb0135","article-title":"Safinamide alleviates hyperalgesia via inhibiting hyperexcitability of DRG neurons in a mouse model of Parkinson's disease","volume":"459","author":"Zhang","year":"2023","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jns.2024.123051_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.752632","article-title":"The effects of safinamide adjunct therapy on depression and apathy in patients with Parkinson\u2019s disease: post-hoc analysis of a Japanese phase 2\/3 study","volume":"12","author":"Hattori","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.123051_bb0145","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3233\/JPD-171143","article-title":"Long-term effects of safinamide on mood fluctuations in Parkinson's disease","volume":"7","author":"Cattaneo","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jns.2024.123051_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262796","article-title":"Effects of rasagiline on Parkinson\u2019s disease questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson\u2019s disease: a post-hoc analysis of clinical trials in Japan","volume":"17","author":"Hattori","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2024.123051_bb0155","doi-asserted-by":"crossref","first-page":"180","DOI":"10.14802\/jmd.22196","article-title":"Safinamide as an adjunct to levodopa in Asian and Caucasian patients with Parkinson\u2019s disease and motor fluctuations: a post hoc analysis of the SETTLE study","volume":"16","author":"Bhidayasiri","year":"2023","journal-title":"J. Mov. Disord."},{"key":"10.1016\/j.jns.2024.123051_bb0160","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharmthera.2013.07.009","article-title":"Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions","volume":"140","author":"Murray","year":"2013","journal-title":"Pharmacol. Ther."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:30:41Z","timestamp":1736184641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24001862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":32,"alternative-id":["S0022510X24001862"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123051","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123051"}}